Skip to main content
SpringerLink
Log in

A phase II study of m-AMSA in patients with primary liver cancer

  • Original Articles
  • m-AMSA Primary Liver Cancer
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

Thirty-five evaluable patients with histologically confirmed primary liver cancer (PLC) were treated with m-AMSA. All patients had measurable disease and an Eastern Cooperative Oncology Group (ECOG) performance status of 1, 2, or 3. m-AMSA 120 mg/M2 IV was given every 21 days. Hemopoietic suppression was the major side-effect. In 26 of 35 patients (25 with leukopenia and five with thrombocytopenia), this toxic effect was documented. There was only one patient who had a partial remission (PR) of 51 weeks' duration, but a no change (NC) status was maintained in 28 patients for at least 6 weeks. The median survival time of all patients on this study was 13 weeks, which compares favorably with most previous studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cain BF, Atwell GJ (1974) The experimental antitumor properties of three congeners of the acridylmethane-sulphon anilide (AMSA) series. Eur J Cancer 10:539

    Google Scholar 

  2. Falson G, Moertel CG, Lavin P, Pretorius FJ, Carbone PP (1978) Chemotherapy studies in primary liver cancer. Cancer 42:2149

    Google Scholar 

  3. Falkson G (1980) Multiple ventricular extrasystoles following administration of 4′ (9-acridinylamino) methanesulphon-manisidide (AMSA). Cancer Treat Rep 64:358

    Google Scholar 

  4. Falkson G, von Hoff D, Klaassen D, du Plessis H, van der Merwe CF, van der Merwe AM, Carbone PP (1980) A phase II study of neocarzinostatin (NSC 157365) in malignant hepatoma. Cancer Chemother Pharmacol 4:33

    Google Scholar 

  5. Legha SS, Gutterman JN, Hall SW, Benjamin RS, Burges MA, Valdivieso M, Bodey GP (1978) Phase I clinical investigation of 4′(9-acridinylamino)-methanesulphon-m-anisidide (NSC 249992), a new acridine derivative. Cancer Res 38:3712

    Google Scholar 

  6. Mellanby E (1933) Suppression of oxygen uptake of cancerous growths. Br Emp Cancer Campaign Annual Report 10:102

    Google Scholar 

  7. Von Hoff DD, Howser D, Gormley P, Bender R, Glaubiger D, Levine AS, Young RC (1978) Phase I study of 4′-(9-acridinylamino)-methanesulphon-m-anisidide (NSC 249992, m-AMSA) using a single dose schedule. Cancer Treat Rep 62:1421

    Google Scholar 

Download references

Author information

Author notes

  1. David J. Klaassen

    Present address: Saskatoon Cancer Clinic, University Hospital, Saskatoon, Saskatchewan, Canada

Authors and Affiliations

  1. University of Ottawa, Ottawa, Ontario, Canada

    David J. Klaassen

  2. Department of Cancer Chemotherapy, University of Pretoria, Private Bag X169, 0001, Pretoria, Republic of South Africa

    Geoffrey Falkson & Buks Coetzer

Authors
  1. Geoffrey Falkson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Buks Coetzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David J. Klaassen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Falkson, G., Coetzer, B. & Klaassen, D.J. A phase II study of m-AMSA in patients with primary liver cancer. Cancer Chemother. Pharmacol. 6, 127–129 (1981). https://doi.org/10.1007/BF00262329

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00262329

Keywords

Search

Navigation